Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 5.

Maul, Julia-Tatjana; Stenner-Liewen, Frank; Seifert, Burkhardt; Pfrommer, Sarah; Petrausch, Ulf; Kiessling, Michael K; Schanz, Urs; Nair, Gayathri; Mischo, Axel; Taverna, Christian; Schmidt, Adrian; Bargetzi, Mario; Stupp, Roger; Renner, Christoph; Samaras, Panagiotis (2017). Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patients. Journal of clinical apheresis, 32(1):21-26.

Kiessling, Michael K; Curioni-Fontecedro, Alessandra; Samaras, Panagiotis; Lang, Silvia; Scharl, Michael; Aguzzi, Adriano; Oldridge, Derek A; Maris, John M; Rogler, Gerhard (2017). Correction: Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. PLoS ONE, 12(1):e0170851.

Kiessling, Michael K; Schuierer, Sven; Stertz, Silke; Beibel, Martin; Bergling, Sebastian; Knehr, Judith; Carbone, Walter; de Vallière, Cheryl; Tchinda, Joelle; Bouwmeester, Tewis; Seuwen, Klaus; Rogler, Gerhard; Roma, Guglielmo (2016). Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening. BMC Genomics, 17(1):723.

Kiessling, Michael K; Curioni-Fontecedro, Alessandra; Samaras, Panagiotis; Lang, Silvia; Scharl, Michael; Aguzzi, Adriano; Oldrige, Derek A; Maris, John M; Rogler, Gerhard (2016). Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. PLoS ONE, 11(1):e0147682.

Kiessling, Michael K; Curioni-Fontecedro, Alessandra; Samaras, Panagiotis; Atrott, Kirstin; Cosin-Roger, Jesus; Lang, Silvia; Scharl, Michael; Rogler, Gerhard (2015). Mutant HRAS as novel target for MEK and mTOR inhibitors. OncoTarget, 6(39):42183-42196.

This list was generated on Sun Sep 23 12:45:09 2018 CEST.